Connect
MJA
MJA

Infectious diseases in Australia — the next decade

Thomas Gottlieb, Bart J Currie and David F M Looke, on behalf of the Executive Council of the Australasian Society for Infectious Diseases
Med J Aust 2012; 196 (5): . || doi: 10.5694/mja12.10116
Published online: 19 March 2012

We need high-voltage infection prevention and management, not short-sighted overuse of antibiotics

As long as human behaviour and medical practices exert unpredictable effects on the microbial environment, infectious disease will continue to challenge and surprise us. Changes in host factors (eg, immunosuppression, hospitalisation), environment (eg, air travel, global warming), and adaptations of microbial pathogens (eg, HIV and severe acute respiratory syndrome [SARS]) can have unanticipated effects. Stated another way, microbial Darwinism is at play.


  • 1 Concord Hospital, Sydney, NSW.
  • 2 Tropical and Emerging Infectious Diseases, Menzies School of Health Research, Darwin, NT.
  • 3 Princess Alexandra Hospital, Brisbane, QLD.



Competing interests:

Thomas Gottlieb is President of the Australasian Society for Infectious Diseases. He has served on advisory boards for Novartis, Pfizer, AstraZeneca, bioMérieux and Janssen-Cilag. Bart Currie is a member of the Executive Council of the Australasian Society for Infectious Diseases. David Looke is Vice-President of the Australasian Society for Infectious Diseases.

  • 1. Burnet M. Natural history of infectious disease. 3rd ed. Cambridge: Cambridge University Press, 1962: 18.
  • 2. Overdevest I, Willemsen I, Rijnsburger M, et al. Extended-spectrum β-lactamase genes of Escherichia coli in chicken meat and humans, the Netherlands. Emerg Infect Dis 2011; 17: 1216-1222.
  • 3. Hardin G. The tragedy of the commons. Science 1968; 162: 1243-1248.
  • 4. Brownlie J, Peckham C, Waage J, et al. Foresight. Infectious diseases: preparing for the future. Future threats. London: Office of Science and Innovation, 2006.
  • 5. Reynolds PN, Turnidge JD, Gottlieb T, Moore MJ. Cross-border patients with tuberculosis. Med J Aust 2011; 195: 523-524. <MJA full text>
  • 6. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
  • 7. Walsh TR. Toleman MA. The emergence of pan-resistant gram-negative pathogens merits a global political response. J Antimicrob Chemother 2012; 67: 1-3.
  • 8. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
  • 9. Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. Nature Med 2004; 10: S70-S76.
  • 10. Corporations: wonder drugs’ wonder. Time 1951; Oct 1. http://www.time.com/time/magazine/article/0,9171,935105,00.html [subscription required] (accessed Feb 2012).
  • 11. Gottlieb T, Nimmo GR. Antibiotic resistance is an emerging threat to public health: an urgent call to action at the Antimicrobial Resistance Summit 2011. Med J Aust 2011; 194: 281-283. <MJA full text>

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.